Why is the Nanosonics (ASX:NAN) share price crashing 16%?

Nanosonics is having a tough day…

| More on:
A woman holds her hands to the side of her face as she sits back in shock at something she is reading or seeing on her computer screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Nanosonics' North American sales agreement with GE Healthcare is ending
  • The company is building up its direct sales team and taking things in house
  • Second half sales to be impacted and costs to increase

The Nanosonics Ltd (ASX: NAN) share price is under pressure on Tuesday morning.

In early trade, the infection prevention company's shares are down 16% to a 52-week low of $4.21.

Why is the Nanosonics share price sinking today?

Investors have been selling down the Nanosonics share price today after it revealed big changes in the North American market.

According to the release, the current GE Healthcare sales model will be revised from 8 February 2022 until the expiry of the current agreement in June 2022. The release does not make clear which party is driving the change.

Under the revised North American sales model, GE Healthcare will consume inventory and transition to a passthrough sales model for its ongoing sales of trophon to be made exclusively through its ultrasound sales team.

What is the new model?

The new model will see Nanosonics manage all inventory, ship, install and train the new GE trophon customers, which will become Nanosonics' customers for the ongoing provision of consumables.

In addition, GE will commence the transition of all existing GE trophon customers to Nanosonics for the ongoing provision of all consumables. During this transition, both companies will have a focus on ensuring a positive customer experience with no disruption in continuity of customer supply.

Positively, the company highlights that it has a well-established logistics operation based in Indianapolis. And with the planned expansion of these resources, it believes it will be well positioned to manage the transition and ensure the ongoing continuity of supply to customers.

Nanosonics' Chief Executive Officer & President, Michael Kavanagh, commented: "The revision to the North American sales model represents another significant milestone in the ongoing growth of the organisation and is consistent with our evolution to an increasingly direct sales model and OEM capital reseller channel strategy over time."

"Discussions are underway with GE Healthcare to commence a new capital reseller agreement at the expiry of the current agreement in June 2022 and we look forward to the opportunity to continue the successful relationship that we have had with GE over the last 10 years," he added.

What financial impact will this have?

The transition is expected to have an overall one-off impact on revenue in FY 2022 in the range of $13 million to $16 million.

This reflects a proportion of the anticipated growth in the second half being deferred to FY 2023 as the transition to the new sales model is implemented.

In addition, the company is going to have to increase its direct sales operations by the end of the fourth quarter of FY 2022. These operations will be tasked with continuing market growth momentum, where management believes a significant opportunity remains for the trophon franchise across new installed base, upgrades and consumables.

The increase in operating expenses associated with the expansion of the North American teams is expected to be approximately $1 million in the second half.

In the meantime, Nanosonics revealed that it expects to report first half sales of $60.6 million later this month. This will be a 41% increase over the prior corresponding period.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Nanosonics Limited. The Motley Fool Australia owns and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »